A Phase 1b Study of Poziotinib in Combination With T-DM1 in Women With Advanced or Metastatic HER2-Positive Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 09 May 2018
At a glance
- Drugs Poziotinib (Primary) ; Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 30 Apr 2018 Planned initiation date changed from 1 Feb 2018 to 1 May 2018.
- 07 Mar 2018 Status changed from not yet recruiting to recruiting.